Servicio de Neumología, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
Arch Bronconeumol. 2012 Oct;48(10):367-71. doi: 10.1016/j.arbres.2012.03.007. Epub 2012 Apr 30.
Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK).
肺癌（LC）是一个严重的健康问题，由于其高发病率和死亡率。手术是治疗这种肿瘤最有效的策略，但近年来，人们正在研究针对肿瘤细胞特定成分的新药，以改善晚期疾病和复发患者的生存率。我们介绍了 LC 的个体化治疗，特别是抑制表皮生长因子受体（EGFR）、血管内皮生长因子（VEGF）和间变性淋巴瘤激酶（ALK）的治疗方法。
